Good morning and welcome. At this time, I would like to introduce the Board of Directors of COSCIENS Biopharma Inc. Peter Puccetti, Anthony Giovinazzo, Ulrich Kosciessa, Ronald Miller, Robert Seager, and David Spear. I will now turn the conference over to Peter Puccetti, Chair of the Board and Chief Executive Officer of COSCIENS. Good morning and welcome to the annual general and special meeting of the shareholders of COSCIENS Biopharma Inc. My name is Peter Puccetti, and as Chair of the Board of the company, I will chair today's meeting. This virtual meeting will be conducted in the same manner as in recent years. While our goal is to replicate the experience you would have if today's meeting were being held in person, there are some rules that we have established for the orderly conduct of the meeting in this virtual format. Number 1, questions in respect of the business of today's meeting may be submitted by registered shareholders and duly appointed proxy holders using the designated Ask a Question field on the web portal. Number 2, when asking a question, please indicate your name and which entity you represent, if any. Number 3, questions will generally be addressed during the question period at the end of the meeting. However, I may deal with questions regarding procedural matters or directly related to the motions during the meeting at an appropriate time. Number 4, voting is open and registered shareholders or duly appointed proxy holders can now vote on each item of business by clicking on the Vote Here button on the web portal. While you are free to vote at any time now and during the meeting, we will also pause briefly at the end of the meeting to allow some additional time to do so prior to closing the polls. Number 5, if you have already submitted your vote in advance of the meeting and you do not wish to change your vote, it is not necessary for you to submit a further vote at this meeting. We will now proceed with the formal portion of today's meeting. To expedite the formal part of the meeting, I will move all motions, and I will not require motions to be seconded. I now call to order the annual general and special meeting of the company's shareholders. With the consent of the meeting, I appoint Joe Zed of Borden Ladner Gervais to act as Secretary of the Meeting. With the consent of the meeting, I appoint [Rita Gutierrez-Fernandez] from Broadridge Investor Communications Corporation as Scrutineer to report on the number of shares represented at this meeting and to tabulate the votes on any ballot taken at this meeting and to report the results of such voting to me. The scrutineer has provided me with a copy of their report, which indicates that holders of no less than 10% of the outstanding shares of the company are in attendance, either in person or by proxy, to permit the meeting to proceed in accordance with the bylaws of the company. A copy of the final report on attendance will be filed with the records of the meeting. I have here the certificate of Broadridge indicating that proper notice of the meeting has been given in accordance with the Canada Business Corporations Act and the bylaws of the company. Accordingly, unless there is an objection, I will dispense with the reading of the notice of meeting. I direct that a copy of the notice with proof of mailing be kept by the secretary with the records of the meeting. The purposes of today's meeting are set out in the Notice of Meeting and Management Information Circular dated May 18th, 2026, copies of which were mailed to shareholders on or about May 27th, 2026, together with the form of proxy and letter of transmittal. These materials are also available under the company's profile on the SEDAR+ website. You should know that proxies lodged before this meeting allow the company's designated proxy holders to cast a significant number of votes. Based on the number of shares represented at this meeting, the company will be able to determine the outcome of all motions that will go to a vote today. I may therefore declare the motions which will go to a vote today as carried, even though all the votes may not have been counted or a final report may not yet be available. I shall do this to keep up the pace of the meeting. I now declare that this meeting is regularly called and properly constituted for the transaction of business. We will now move to the formal part of today's agenda. The first item of business is the presentation of the company's consolidated financial statements for the year ended December 31st, 2025, and the auditor's report thereon. Unless there is an objection, I will dispense with the reading of the auditor's report. The company will entertain questions with respect to the financial statements of the company in the general question period. The next item of business is the appointment of the auditors of the company for the ensuing year, and to authorize the directors of the company to fix the remuneration of the auditors. The board of directors has approved, subject to shareholder confirmation, the appointment of Deloitte LLP as the auditors of the company. I move that Deloitte LLP be appointed auditors of the company until the next annual meeting of shareholders, and that the board of directors be authorized to fix their remuneration. Are there any questions regarding procedural matters or directly related to this motion that require addressing at this time? I understand there are no such questions, and accordingly, we shall proceed to discuss the next item of business. The next item of business is the re-election of six individuals to the board of directors being Anthony Giovinazzo, Ulrich Kosciessa, Ronald Miller, Robert Seager, David Spear, and myself, Peter Puccetti. Each of these six individuals have been nominated as directors until their successors are elected or appointed. Each nominee is qualified to act as a director under the provisions of the Canada Business Corporations Act, and each has confirmed that he is prepared to serve as a director. The company did not receive notice of any director nominations in connection with the meeting in accordance with its advance notice bylaw. Accordingly, the only persons eligible to be nominated for election to the board are the nominees as outlined in the circular. Since there are no other nominations, I move a motion to elect the directors. Are there any questions regarding procedural matters or directly related to this motion that require addressing at this time? I understand there are no such questions, and accordingly, we shall proceed to discuss the next item of business. The final item of business is to consider, and if deemed advisable, to approve a special resolution, the full text of which is set forth in the circular to approve and authorize the proposed share consolidation and share split, which involves consolidating the common shares of the company on the basis of a ratio of one post-consolidation common share for every 150 pre-consolidation common shares, and subsequently splitting the post-consolidation common shares on the basis of 50 common shares for every one post-consolidation common share. Shareholders holding fewer than 150 common shares prior to the effective date of the consolidation will cease to hold such common shares and will be entitled to an amount in cash per pre-consolidation common share equal to $1.60. To be effective, this resolution must be approved by not less than 66 and two-thirds percent of the votes cast by holders of common shares, present in person or by proxy at this meeting. In addition, this resolution must be approved by a simple majority of the votes cast, excluding votes cast in respect of common shares beneficially owned, directed by certain insiders, as more particularly described in the circular. I move that the special resolution in the form outlined on pages 38 and 39 of the circular be approved. Are there any questions regarding procedural matters or directly related to this motion that require addressing at this time? I understand there are no such questions, and accordingly, we shall proceed to discuss the next item of business. As mentioned at the outset, voting on all of these items has been open since the beginning of the meeting. We will now proceed to give another minute for any registered shareholders or duly appointed proxy holders who have not already done so to complete the electronic ballot by clicking on the Vote Here button on the web portal to access the voting page. If you have already submitted your vote and you do not wish to change your vote, it is not necessary for you to submit a further vote at this meeting. Once the electronic balloting closes, the voting page will disappear, and your votes will automatically be submitted. Okay. The polls have now closed, and the voting period has ended. We will now pause for a few moments while the scrutineer compiles the report regarding the results of voting. We will reconvene in a few moments with the voting results. Thank you for waiting. I have received the scrutineer's preliminary report and confirm the following. Each of the six eligible nominees, being Anthony Giovinazzo, Ulrich Kosciessa, Ronald Miller, Peter Puccetti, Robert Seager, and David Spear, have been elected as directors to serve until the next annual meeting of shareholders or until such time as their successors have been duly elected or appointed, unless their office is vacated earlier. The appointment of Deloitte LLP as the auditors of the company has been approved, and the board of directors of the company has been authorized to fix their remuneration. Number 3, the special resolution approving an amendment to the company's articles to complete a share consolidation and share split has been approved. I direct that the voting results be included in the minutes of this meeting, announced in a press release, and filed on SEDAR+ and EDGAR. There is no further business to be brought before this meeting, I move that the formal portion of today's meeting be concluded. The formal business of the meeting of shareholders of the company has now been completed, I would like to turn to any questions submitted during the meeting which have not already been addressed and to invite shareholders and duly appointed proxy holders to ask questions to the extent they have not already done so by using the Ask a Question field on the web portal. When asking your question, please state your name and the entity you represent, if any. Please limit your questions to topics relating to today's subject matter and keep your questions short and to the point. We will now give attendees a brief moment to type in their questions. We had one question, which was, it was noticed on the Health Canada site license holders list that [Cipro Inc]. site license is discontinued. If the company failed to keep the Health Canada site license, does that mean no [YBG capsules], no PGX? What technology now they are doing? I guess that means what technology are they now pursuing. Why didn't the company cut the big budget and employee-related R&D of nutraceuticals? I don't want to go into any specifics. Let me just generally answer that we continue to evaluate our strategic plans. We have been doing for the last while, and we continue to focus our energy on PGX and all associated costs and relationships. We've done everything with a mind towards rational and common sense cost-cutting and strategic focus. I can't be more specific at this moment, but you can certainly assume that we're applying a lot of common sense to the situation. I don't believe there are any other questions at this point. Let me just check. Yes, that's right. There being no further questions, we are now concluding the question and answer portion of the meeting. Operator. Thank you for your time. Goodbye.